Journal
JOURNAL OF IMMUNOLOGY
Volume 165, Issue 10, Pages 5906-5912Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.165.10.5906
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI 43668] Funding Source: Medline
- NIEHS NIH HHS [ES03819] Funding Source: Medline
Ask authors/readers for more resources
CpG oligodeoxynucleotides (CpG-ODN) administered during Ag sensitization or before Ag challenge can inhibit allergic pulmonary inflammation and airway hyperreactivity in murine models of asthma, In this study, we investigated whether CpG-ODN ran reverse an ongoing allergic pulmonary reaction in a mouse model of asthma, AKR mice were sensitized with conalbumin followed by two intratracheal challenges at weekly intervals. CpG-ODN was administered 24 h after the first Ag challenge. CpG-ODN administration reduced Ag-specific IgE levels, bronchoalveolar lavage fluid eosinophils, mucus production, and airway hyperreactivity. We found that postchallenge CpG-ODN treatment significantly increased IFN-gamma concentrations and decreased IL-13, IL-4, and IL-5 concentrations in bronchoalveolar lavage fluids and spleen cell culture supernatants. Postchallenge CpG-ODN treatment also increased B7.1 mRNA expression and decreased B7.2 mRNA expression in lung tissues. These results suggest that CpG-ODN may have potential for treatment of allergic asthma by suppressing Th2 responses during IgE-dependent allergic airway reactions, The down-regulation of Th2 responses by CPG-ODN may be associated with regulation of the costimulatory factors B7.1 and B7.2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available